GE Healthcare wins FDA clearance for its FlightPlan for Liver imaging system, developed to streamline liver embolization procedures.
The system has been on the market in Europe, Latin America and Asia since last year and has already been installed in 10 countries, GE reported.
FlightPlan for Liver helps plan liver embolization interventions by providing an "3D road-map" of the vessels that lead to a lesion, helping the physician guide a catheter to a target artery, according to a press release.
The process of identifying blood vessels that feed a liver tumor can be time-consuming and existing solutions can require significant amounts of radiation and contrast media.
The GE technology aims to make the intricate and often difficult process of preparing a liver embolization simpler.
"With FlightPlan for Liver, interventionalists can gain confidence in identifying tumor-feeding vessels and be more selective when planning liver embolization," GE Healthcare premium angiography, detection & guidance solutions general manager Chantal Le Chat said in prepared remarks.
GE shares were down 0.4% to $20.95 as of about 1:45 p.m. today.
Halloran expands clinical finance services and licenses leading industry financial forecasting tool...
Share prices tick up for C.R. Bard after it reports a 1st-quarter earnings beat.
Here's a look at some of the top legal news stories for medical device companies this week: Medtech...
Edwards Lifesciences CEO Michael Mussallem says the company now expects the FDA to approve its next-...
Reva Medical begins enrolling patients in Europe for a trial of its Fantom bioresorbable stent.